Early assessment of KRAS mutation in cfDNA correlates with risk of progression and death in advanced non-small-cell lung cancer.

Br J Cancer · 2020 · PMC7341732 · PMID 32376889

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a clear trendno p-value reported

A clear trend for shorter OS was also seen when we considered the increase T1–T2 (Supplementary Figs. 3 and 5g ) and became statistically significant when we evaluated the impact of the presence of KRAS mutation at T3 and its increase T1–T3 ( p = 0.0031 and p = 0.018; Supplementary Figs. 3 and 5f, h ).

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.